WVU Medicine is playing a lead role in a national clinical study of a minimally invasive surgical procedure for people who've ...

"They’re priced for profits, not patients.” That’s the critique from Hims & Hers Health’s buzzy — and controversial — Super ...

"They’re priced for profits, not patients.” That’s the critique from Hims & Hers Health’s buzzy — and controversial — Super ...

Novo Nordisk shares dropped due to CagriSema trial results but have long-term upside. Learn why NVO stock is a Strong Buy ...

For years, people taking Ozempic or other drugs in the same class for diabetes and weight loss have noticed the medicines don ...

But faced with a $1,200 monthly price tag for her weight loss medication ... and potential jail time. These arrests can have lasting impacts on employment opportunities and professional licenses ...

Two healthcare stocks that may or may not be boring, but that regardless look like strong growth stocks to invest in this ...

Among those who adhered to treatment, the high-dose group achieved an average weight loss ... Zepbound (tirzepatide), which helped patients shed 20.9% of their weight at the same 72-week time ...

Its lineup features several blockbusters, including its popular diabetes and weight loss medicines, Mounjaro and Zepbound ... was able to hear for the first time. Eli Lilly's late-stage pipeline ...

The US Food and Drug Administration (FDA) has declared an end to the shortage of tirzepatide, the active ingredient in Eli Lilly’s popular weight loss medication Zepbound and diabetes drug Mounjaro.

Singh said, “What we think is that over a period of time in diabetes ... who have either have lost weight or will take Zepbound to lose 15% of their body weight. When the desired weight loss ...

This study provides valuable insight into the increasing use of obesity drugs. The rising prescription numbers suggest that ...